The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Philippe Moreau
No relevant relationships to disclose
David Avigan
No relevant relationships to disclose
Kenneth Carl Anderson
No relevant relationships to disclose
Donna Ellen Reece
Honoraria - Amgen; Celgene; Janssen; Onyx; Otsuka
Research Funding - Bristol-Myers Squibb; Celgene; Janssen; Merck; Millennium; Novartis; Otsuka
Expert Testimony - Onyx
Jesus San Miguel
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Merck; Millennium; Novartis; Onyx
MarĂ­a-Victoria Mateos
No relevant relationships to disclose
Dianna Wu
Employment or Leadership Position - Merck
Stock Ownership - Merck
Kenneth Emancipator
Employment or Leadership Position - Merck
Marisa Dolled-Filhart
Employment or Leadership Position - Merck
Christine Gause
Employment or Leadership Position - Merck
Holly Brown
Employment or Leadership Position - Merck
Karl Heath
Employment or Leadership Position - Merck
Robert Iannone
Employment or Leadership Position - Merck
Shelonitda Rose
Employment or Leadership Position - Merck
Robert Z. Orlowski
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Onyx
Honoraria - Bristol-Myers Squibb (I); Celgene; Merck; Millennium; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Onyx